PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal). The three posters, which are listed below, summarize proteomic analyses from the completed SEQUE ...

PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today that the Company's president and CEO, Lisa Ricciardi will present at the TD Cowen 44th Annual Health Care Conference taking place March 4-6, 2024. During her presentation, Ms. Ricciardi will highlight Cognition's pipeline progress, including upcoming clinical milestones and recent corporate achievem ...

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that collaborators at the University of Edinburgh, Scotland published findings in the journal, Acta Neuropathologica, (doi: 10.1007/s00401-023-02679-6) that provide new insight into the biology of Alzheimer's disease that is consistent with our understanding of the role the σ-2 receptor has in regulating Aβ oligomer binding.  Usin ...

Table of Contents ● the size and growth of the potential markets for our product candidates and our ability to serve those markets; ● economic uncertainty resulting from actual or perceived inflation or banking stability; You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different fro ...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer John Doyle - Chief Financial Officer Tony Caggiano - Chief Medical Officer and Head, R&D Conference Call Participants Charles Duncan - Cantor Jay Olson - Oppenheimer Aydin Huseynov - Ladenburg Operator Good morning, ladies and gentlemen and welcome to Cognition Therapeutics Second Quarter 2 ...

1. Description of Business and Financial Condition On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333- 268992) (the "Shelf") with the Securities and Exchange Commission ("SEC") in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into ...

Net cash used in investing activities for the three months ended March 31, 2023 and 2022 was less than $0.1 million and $0.1 million, respectively, related to a decreased purchase of fixed assets. Overall, the change in net cash used in investing activities was insignificant. Net cash used in financing activities was less than $0.1 million for the three months ended March 31, 2023, and net cash provided by financing activities was $0.1 million for the three months ended March 31, 2022. We have entered into ...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2022 Earnings Conference Call March 23, 2023 8:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer Andrew Einhorn - Interim Chief Financial Officer Tony Caggiano - Chief Medical Officer and Head of R&D Conference Call Participants Charles Duncan - Cantor Fitzgerald Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Operator Good morning, ladies and gentlemen, and welcome to Cog ...

Table of Contents SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40886 COGNITION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4365359 (State of Other Jurisdiction of incorporation or Organization) ...

Table of Contents 2500 Westchester Ave. Purchase, NY 10577 (Address of Principal Executive Offices) (412) 481-2210 (Registrant's telephone number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...